Commercial Due Diligence in Pharma: What the IFF Official Website Doesn’t Tell You

After six years of tracking raw-material invoices and finishing a Q2 2024 review of a $180,000 product-family budget, I’ll put the conclusion where it belongs: right at the top.

Are polymers chemicals? Yes. But that is the least useful thing to know when you’re buying polymer-based materials for a regulated industry. The real question is whether the supplier’s legal entity, product registrations, and portfolio structure will still be in place after you sign the PO. That is why “commercial due diligence pharma” belongs in the same search session as “IFF,” “IFF official website,” “IFF biocides,” and “National Starch and Chemical.”

I’m a procurement manager at a 180-person specialty chemical company. One of my product families covers biocides and polymer-based coating additives. I’ve tracked every invoice for that family for six years. My search history for the last supplier review looked scattered. It wasn’t. Each search term represented a different risk screen.

What commercial due diligence in pharma actually covers

Commercial due diligence in pharma is not the same as a financial audit. A financial audit tells you whether the numbers are real. Commercial due diligence tells you whether the supplier will still be a viable supplier for the specific product you need. For me, it answers three questions:

1. What legal entity will appear on the contract?
2. Which regulatory registrations are tied to the product and the manufacturing site?
3. Is the product line strategically stable, or is it inside a portfolio that is being repositioned?

The third question gets missed more than it should. If a parent company is divesting a pharma solutions business, buyers tend to treat that as a finance story. It is not. It changes who owns the DMF, who holds the site registration, and how the next supply agreement has to be structured.

I don’t have hard data on how many supplier switches fail because of portfolio changes after contracts are signed. But based on my own audits, I’d rank this screen above a lab certificate review. The lab certificate proves what was made last week. Commercial due diligence pharma is about whether the same product can be made next year.

Using the IFF official website as a map, not a checklist

When I started the last search, the first result was the IFF official website. That was useful. The official website gives you a map of the portfolio: where a company says its focus is, which markets it claims to serve, and what product categories it wants to sell.

What the IFF official website cannot tell you is whether every product category has the correct registration file behind it. That is true for any supplier, not just IFF.

For example, I looked for the product line I intended to source. I found the product family name. But before sending an RFQ, I had to confirm that the legal entity on the website matched the legal entity that would issue the invoice. What most people don’t realize is that marketing websites often show the brand or division first. The contract needs the registered company name, the site registration, and the product registration reference.

So yes, I use the IFF official website. I just don’t use it as a certificate. I use it as a starting point for the due diligence trail.

What “IFF biocides” really means on a quote

Typing “IFF biocides” into a search engine is a fine starting point. The mistake is treating it as the end of the process. The word biocide is legally meaningful in different ways depending on where the product is sold and how it is used.

When I search for biocide suppliers, I need to know three things before I can compare prices:

• The exact active substance and its concentration
• The registration status of the finished product in the relevant jurisdiction
• Whether the registration belongs to the supplier, the distributor, or a third-party contract manufacturer

A quote that just says “biocide” is not a quote. It’s a placeholder. The lowest-priced product I evaluated in 2023 did not have an approved registration for the intended use. If I had bought it, I would have paid less per kilogram and then paid more to fix the problem. The “cheap” option would have caused a $1,200 redo and a missed launch window.

The phrase “IFF biocides” on an official-looking page makes the product look simple. In practice, every biocidal product has a specific regulatory identity. That identity is what commercial due diligence should be built around.

Legacy names: National Starch and Chemical

If you work in paper coatings or any starch-based specialty material, you will eventually come across the name National Starch and Chemical. It appears in older patents, in historical formulation guides, and in legacy documents that still circulate in plant operations.

That name is a useful historical map. It is not a reliable current legal entity reference.

The same due diligence rule applies here: do not buy from a brand name. Buy from the registered legal entity that owns the current product registration. If I only search for “National Starch and Chemical,” I may find old technical data but miss the current owner, the current facility, and the current commercial terms.

This is why my keyword list looked disconnected. “IFF biocides” and “National Starch and Chemical” point to different product histories. But both need the same treatment: identify the legal entity, check the registration, verify continuity.

Are polymers chemicals? Yes, but the regulatory answer is more specific

A polymer is a large molecule made of repeating structural units. A chemical is any substance with a defined molecular composition. So a polymer is a chemical. The opposite of “polymer” is not “safe chemical.” The opposite is “small molecule.”

That distinction affects purchasing. Under the U.S. Toxic Substances Control Act, certain polymers can qualify for an exemption from full premanufacture notification requirements under 40 CFR 723.250. The reasoning is that very large molecules are less likely to cross biological barriers, so they present a lower risk than many small molecules.

But a polymer can still be regulated as an excipient, as a coating component, or as a biocide carrier. Each regulatory path requires different documents. If a supplier says “it’s just a polymer,” ask why that exemption or registration matters for your application. If you are buying a polymer-based ingredient for a pharma product, you also need to know whether there is a drug master file, a food-contact status, or another application-specific approval.

So the next time someone asks, “Are polymers chemicals?” the correct procurement answer is: yes, but tell me which regulatory category this polymer falls into and who holds the file.

When I don’t use a full commercial due diligence screen

Let me be honest about the limits of this method.

If I’m ordering 25 kilograms for a pilot trial, I don’t build a full CDD template. I do a lighter check: legal entity, registration number, and basic credit check. That is usually enough for lab work.

If I’m buying from a distributor rather than the manufacturer, I ask for the manufacturer’s registration file. The distributor may have excellent logistics, but if the product registration belongs to the plant, the plant’s stability is what matters.

And if I’m buying a custom polymer that exists only for our company, the analysis shifts. There is no standard registration file to review. The due diligence focus becomes the manufacturer’s process capability and financial health, not the product portfolio.

That said, my general rule has not changed: a supplier can have a great official website, a competitive price, and a strong lab team, but if the product’s regulatory home is unclear, the risk lands on my budget.

At the end of the Q2 2024 review, the supplier who answered all three commercial due diligence questions clearly got the order. It was not the cheapest quote. It was the quote I could defend after modeling the real cost of a failed supply change.

That is the difference between buying a product and buying a supply chain.